Biogen (BIIB) Common Equity (2009 - 2026)
Biogen (BIIB) posted quarterly Common Equity of $18.8 billion for Q2 2026, up 6.88% year-over-year from $17.6 billion in Q2 2025, and up 1.05% quarter-over-quarter from $18.7 billion in Q1 2026.
Biogen (BIIB) Common Equity (2009 - 2026) Analysis & Trends
Biogen's Common Equity history runs 18 years deep, the most recent figure standing at $18.8 billion for Q2 2026.
- In Q2 2026, Common Equity rose 6.88% year-over-year to $18.8 billion; the TTM figure through Jun 2026 stood at $18.8 billion (up 6.88% YoY), while the FY2025 annual figure was $18.3 billion, down 5.21% from the prior year.
- Common Equity for Q2 2026 stood at $18.8 billion, up from $18.7 billion in the prior quarter.
- The five-year high for Common Equity was $19.3 billion in Q4 2024, with the low at -$171.2 million in Q3 2025.
- The 5-year median for Common Equity is $15.0 billion (2023), against an average of $14.6 billion.
- The sharpest annual moves came in 2024 and 2025: Common Equity soared 30.14% in 2024, then slumped 101.05% in 2025.
- Biogen's Common Equity stood at $13.4 billion in 2022, then grew by 10.54% to $14.8 billion in 2023, then surged by 30.14% to $19.3 billion in 2024, then slipped by 5.21% to $18.3 billion in 2025, then climbed by 3.24% to $18.8 billion in 2026.
- Business Quant data shows BIIB's Common Equity at $18.8 billion in Q2 2026, $18.7 billion in Q1 2026, and $18.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 18.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.85 Bn |
| Mar 31, 2026 | 18.65 Bn |
| Dec 31, 2025 | 18.26 Bn |
| Sep 30, 2025 | -171.20 Mn |
| Jun 30, 2025 | 17.63 Bn |
| Mar 31, 2025 | 16.98 Bn |
| Dec 31, 2024 | 19.26 Bn |
| Sep 30, 2024 | 16.36 Bn |
| Jun 30, 2024 | 15.89 Bn |
| Mar 31, 2024 | 15.21 Bn |
| Dec 31, 2023 | 14.80 Bn |
| Sep 30, 2023 | 14.48 Bn |
| Jun 30, 2023 | 14.46 Bn |
| Mar 31, 2023 | 13.79 Bn |
| Dec 31, 2022 | 13.39 Bn |
| Sep 30, 2022 | 12.77 Bn |
| Jun 30, 2022 | 11.86 Bn |
| Mar 31, 2022 | 11.22 Bn |
| Dec 31, 2021 | 10.96 Bn |
| Sep 30, 2021 | 10.88 Bn |